24/7 Patient Assistance: 760-405-8205
24/7 Patient Assistance: 760-405-8205
Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pleural Mesothelioma Testicular Mesothelioma
Hospitals & Clinics
specialties & services
Dr. Soler started his medical career in his native town Barcelona, graduating from the Universidad Autonoma medical school in 1977. Dr. Roman Soler also completed residency at the same university. For his fellowship Dr. Roman Soler moved to the United States to attend the courses of the University MD Anderson Cancer Center. Currently acting as the chairman of the department of oncology at the Montefiore Medical Center, Dr. Soler specializes and focuses on the treatment of mesothelioma. With a vast career, spanning two continents, Dr. Roman Soler received several awards and had many articles and works published, mainly regarding treatment methods for mesothelioma.
Universidad Autonoma - 1977
Medical School
Universidad Autonoma
Residency
University MD Anderson Cancer Center
Fellowship
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
Burke Rehabilitation Hospital
Languages: English/Spanish
(914) 597-2500
785 Mamaroneck Ave
White Plains, New York 10605 
Montefiore Medical Center
Languages: English/Spanish
(718) 405-8505
1695 Eastchester Rd
Bronx, New York 10461
SBH Health System
Languages: English/Spanish
(718) 960-9000
4422 Third Ave
Bronx, New York 10457
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib
Ling YH1, Li T, Perez-Soler R, Haigentz M Jr.
See more >>
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK
Yi-He Ling, Ruoping Lin, Roman Perez-Soler, Mol. Pharmacol., 74 (2008)
See more >>
Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene
Li T1, Ling YH, Perez-Soler R.
See more >>